Gosset Year Founded
1996
Ownership
Private
Employees
~500
Stage
Phase 2
Modalities
Agensys General Information
Company developed multiple antibody and ADC programs, with lead programs enfortumab vedotin in Phase 2 for bladder cancer and AGS-16C3F for renal cell carcinoma. Was acquired by Astellas in 2007 for $537M and later wound down in 2017-2018.
Contact Information
Drug Pipeline
enfortumab vedotin
Phase 2Key Partnerships
Merck & Co, Seattle Genetics, Astellas, Genentech, Sanofi Pasteur
Agensys Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Later Stage VC | Jul 12, 2007 | $41.3M | Completed | Phase 2 |
To view Agensys's complete valuation and funding history, request access »
Agensys Investors
Private donors and "angel investors," many of whom were grateful patients of UCLA physicians
Investor Type: Venture Capital
Holding: Minority